Clovis Oncology Stock News

Despite optimistic expectations concerning label expansion for Clovis Oncology Inc's (NASDAQ: CLVS) Rubraca to include prostate cancer, an analyst at BofA Securities is turning bearish on the stock. T

Upgrades JP Morgan upgraded the stock for Big Lots Inc (NYSE: BIG) from Underweight to Neutral. In the fourth quarter, Big Lots showed an EPS of $2.39, compared to...

CRISPR is key to the cancer drugs that Tango Therapeutics is developing, but the startup isn’t out to edit disease-causing genes. Tango uses technology as

Inspire Medical Systems (NYSE:INSP) initiated with Overweight rating and $74 (19% upside) price target at Piper Sandler.Prevail Therapeutics (NASDAQ:PRVL) initiated with Overweight rating and $20 (46%

Clovis Oncology (CLVS) closed the most recent trading day at $6.10, moving +0.49% from the previous trading session.

Clovis Oncology (CLVS) closed the most recent trading day at $6.10, moving +0.49% from the previous trading session.

Clovis Oncology (NASDAQ:CLVS) fell 2.6% on Tuesday . The stock traded as low as $6.25 and last traded at $6.26, 220,041 shares traded hands during trading. A decline of 97% from the average session vo

Equities research analysts expect that Clovis Oncology (NASDAQ:CLVS) will announce sales of $42.80 million for the current quarter, according to Zacks Investment Research. Four analysts have issued es

Clovis Oncology (NASDAQ:CLVS) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a report released on Tuesday, BidAskClub reports. Other analysts hav

Brokerages forecast that Clovis Oncology (NASDAQ:CLVS) will post earnings of ($1.27) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimat

So far Saturday, March 28, NASDAQ is down -1.28% and the S&P is up 0.15%. Let’s take a look at

So far Friday, March 27, NASDAQ is up 1.48% and the S&P is up 1.28%. Here are this morning’s most